|Bid||39.50 x 900|
|Ask||50.90 x 800|
|Day's range||49.70 - 51.60|
|52-week range||32.47 - 62.16|
|Beta (5Y monthly)||1.63|
|PE ratio (TTM)||2.17|
|Earnings date||29 Jul 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||65.33|
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios Pharmaceuticals (AGIO) files a MAA in Europe for its most advanced drug, mitapivat, to treat adults with pyruvate kinase deficiency.
Agios (AGIO) submits a new drug application to the FDA for its lead candidate, mitapivat, for treating adults with pyruvate kinase deficiency. Stock up.